{
    "ticker": "RHTX",
    "name": "RedHill Biopharma Ltd.",
    "description": "RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and other conditions. Founded in 2009, RedHill is dedicated to addressing unmet medical needs through its robust pipeline of proprietary products. The company's lead investigational product, RHB-105, is a novel therapy aimed at treating peptic ulcers and has shown promising results in clinical trials. RedHill also focuses on the development of treatments for COVID-19, including its oral antiviral candidate, which is currently undergoing evaluation in clinical studies. The company operates with a strong commitment to advancing healthcare solutions and improving patient outcomes. With a diverse portfolio of products in various stages of development, RedHill is well-positioned to make significant contributions to the biopharmaceutical industry. Its mission is to provide effective therapies that enhance the quality of life for patients suffering from chronic and acute conditions. RedHill's strategic partnerships and collaborations with leading research institutions further bolster its innovative capabilities, allowing the company to stay at the forefront of biopharmaceutical advancements.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Jerusalem, Israel",
    "founded": "2009",
    "website": "https://www.redhillbio.com",
    "ceo": "Micah J. W. W. K. K. (Mickey) Heller",
    "social_media": {
        "twitter": "https://twitter.com/redhillbio",
        "linkedin": "https://www.linkedin.com/company/redhill-biopharma/"
    },
    "investor_relations": "https://www.redhillbio.com/investor-relations",
    "key_executives": [
        {
            "name": "Micah J. W. W. K. K. (Mickey) Heller",
            "position": "CEO"
        },
        {
            "name": "Gidi Barak",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gastrointestinal Therapies",
            "products": [
                "RHB-105",
                "RHB-104"
            ]
        },
        {
            "category": "Infectious Disease Treatments",
            "products": [
                "RHB-107"
            ]
        }
    ],
    "seo": {
        "meta_title": "RedHill Biopharma Ltd. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore RedHill Biopharma Ltd., a leader in developing innovative therapies for gastrointestinal diseases and COVID-19. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "RedHill Biopharma",
            "Biopharmaceuticals",
            "Gastrointestinal Disease",
            "COVID-19 Treatments",
            "RHB-105"
        ]
    },
    "faq": [
        {
            "question": "What is RedHill Biopharma known for?",
            "answer": "RedHill Biopharma is known for developing innovative therapies for gastrointestinal diseases and COVID-19."
        },
        {
            "question": "Who is the CEO of RedHill Biopharma?",
            "answer": "Micah J. W. W. K. K. (Mickey) Heller is the CEO of RedHill Biopharma Ltd."
        },
        {
            "question": "Where is RedHill Biopharma headquartered?",
            "answer": "RedHill Biopharma is headquartered in Jerusalem, Israel."
        },
        {
            "question": "What are RedHill Biopharma's main products?",
            "answer": "RedHill Biopharma's main products include RHB-105 and RHB-104 for gastrointestinal diseases."
        },
        {
            "question": "When was RedHill Biopharma founded?",
            "answer": "RedHill Biopharma was founded in 2009."
        }
    ],
    "competitors": [
        "GILD",
        "MRNA",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "JNJ",
        "PFE"
    ]
}